GlassScriptPhysician profile
Nan Sandar
NPI 1376785634
$4,932.67
in general payments reported to CMS, 2019-2025
25 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $679 · 2021: $763 · 2022: $437 · 2023: $529 · 2024: $566 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.69 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,128.93 | 2019-2025 | |
| Abbvie INC. | $874.53 | 2019-2025 | Mavyret, Linzess, Viberzi |
| Intercept Pharmaceuticals, INC. | $303.49 | 2019-2025 | Ocaliva |
| Janssen Biotech, INC. | $265.19 | 2021-2025 | Tremfya, Stelara, Remicade |
| Phathom Pharmaceuticals, INC. | $160.74 | 2024-2025 | Voquezna |
| Amgen INC. | $157.14 | 2025 | Uplizna |
| Novo Nordisk INC | $145.44 | 2025 | Wegovy |
| Redhill Biopharma INC. | $117.22 | 2020-2021 | |
| Celgene Corporation | $112.84 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.23 | 2021 | |
| Braintree Laboratories, INC. | $74.36 | 2019-2021 | |
| Shionogi INC | $69.77 | 2019 | |
| Madrigal Pharmaceuticals | $65.94 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $62.21 | 2023 | |
| Intra-Sana Laboratories | $46.41 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $45.17 | 2023-2025 | Iqirvo, Bylvay |
| Allergan, INC. | $37.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.07 | 2023-2024 | Entyvio |
| Qol Medical, LLC | $22.00 | 2020 | |
| Celltrion USA INC. | $19.98 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $18.70 | 2019 | |
| Merck Sharp & Dohme LLC | $18.62 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.14 | 2019 | |
| Vivus LLC | $16.30 | 2024 | Pancreaze |
| Aimmune Therapeutics, INC. | $15.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nan Sandar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.